70 FR 134 pg. 40689 - Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Provisional Patent Applications Concerning Inhibitors of Type F Botulinum Neurotoxin Proteinase Activity
Type: NOTICEVolume: 70Number: 134Page: 40689
FR document: [FR Doc. 05-13856 Filed 7-13-05; 8:45 am]
Agency: Defense Department
Sub Agency: Department of the Army
Official PDF Version: PDF Version
DEPARTMENT OF DEFENSE
Department of the Army
Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Provisional Patent Applications Concerning Inhibitors of Type F Botulinum Neurotoxin Proteinase Activity
AGENCY:
Department of the Army, DoD.
ACTION:
Notice.
SUMMARY:
In accordance with 37 CFR 404.6 and 404.7, announcement is made of the availability for licensing of the invention set forth in U.S. Provisional Patent Application Serial No. 60/656,551 entitled "Inhibitors of Type F Botulinum Neurotoxin Proteinase Activity," filed February 17, 2005; as well as the invention set forth in related U.S. Provisional Patent application Serial No. 60/660,024 entitled "Inhibitors of Type F Botulinum Neurotoxin Proteinase Activity," filed February 23, 2005. The United States Government, as represented by the Secretary of the Army, has rights in this invention.
ADDRESSES:
Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-ZA-J, 504 Scott Street, Fort Detrick, Frederick, MD 21702-5012.
FOR FURTHER INFORMATION CONTACT:
For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul Mele, Office of Research Technology Assessment, (301) 619-6664, both at telefax (301) 619-5034.
SUPPLEMENTARY INFORMATION:
Botulinum neurotoxins (BoNTs A-G) are zinc metalloendoproteases that exhibit extraordinary specificities for proteins involved in neurotransmitter release. In view of the extreme toxicities of these molecules, their applications in human medicine, and potential for misuse, it is of considerable importance to elucidate the mechanisms underlying substrate recognition and to develop inhibitors, with the ultimate goal of obtaining anti-botulinum drugs.
Brenda S. Bowen,
Army Federal Register Liaison Officer.
[FR Doc. 05-13856 Filed 7-13-05; 8:45 am]
BILLING CODE 3710-08-M